Keyword: Food and Drug Administration (FDA)

Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.

SIGA Technologies tested its smallpox drug in 359 healthy volunteers to demonstrate safety and relied on animal data to show efficacy.

Spero Therapeutics’s lead candidate will be the subject of a federal interagency collaboration to test the drug against biological threats.

GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax—one of the most common forms of malaria.

Already knowing Theranos’ story doesn’t make "Bad Blood" a less interesting read but offers a rare connection to its players as the scandal unfolds.

Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.

Modus Therapeutics raised over 140 million Swedish krona, or about $15.7 million, to advance clinical studies of sevuparin in sickle cell disease.

The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.

Cel-Sci won a yearslong arbitration battle with inVentiv, now known as Syneos Health, over breach of contract and missed phase 3 enrollment promises.

Novocure named Pritesh Shah chief commercial officer, to lead the tumor-treating device manufacturer’s international business units.